NEOGEN CORP
Close on Oct 19, 2026
- Market cap
- $2.54B
- P/E (TTM)
- –
- Dividend yield
- –
About Neogen
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Neogen Corporation develops, manufactures, and markets food and animal safety products and services. The Food Safety segment provides diagnostic test kits, culture media, and data management software to detect pathogens, toxins, allergens, and spoilage organisms, serving food and feed processors, agricultural operations, and regulatory agencies. The Animal Safety segment provides veterinary instruments, animal care products, pharmaceuticals, pest control solutions, and genomics testing services to livestock producers, veterinarians, and retailers.
The company operates globally, maintaining facilities in twenty-eight countries outside the United States, alongside distributors across more than one hundred countries. It conducts manufacturing and genomics laboratory services across facilities in the United States, the United Kingdom, Ireland, Brazil, Australia, China, and Canada. Neogen Corporation is headquartered in Lansing, Michigan.
Summary of the business section of Neogen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NEOGEN CORP
- Founded
- 1981
- Headquarters
- Lansing, MI
- Address
- 620 Lesher Place 48912
- Phone
- (517) 372-9200
- Website
- neogen.com
- Employees
- 2,636, May 31, 2026
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Michigan
- Fiscal year ends
- May 31
- Auditor
- BDO USA, P.C., Grand Rapids, MI
Stock & identifiers
- Ticker
- NEOG
- Exchange
- Nasdaq
- Shares outstanding
- 218M, Jun 30, 2026
- Public float
- $972.14M, Nov 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jul 30, 2021; 2-for-1, Jun 7, 2021; 4-for-3, Dec 29, 2017; 3-for-2, Oct 31, 2013; 3-for-2, Oct 31, 2013; 3-for-2, Dec 16, 2009; 3-for-2, Sep 5, 2007; 5-for-4, Jan 2, 2004
- SEC CIK
- 711377
- CUSIP
- 640491106
- ISIN
- US6404911066
- LEI
- 549300HJT9FC36N4UW43
- EIN
- 38-2367843
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mikheal Nassif | CEO, Director | 26,729 |
| John Patrick Moylan | Chief Accounting Officer | 29,331 |
| Jennifer Evans Stacey | Chief Legal Officer | 38,627 |
| Tamara A. Ranalli | Senior Vice President | 25,751 |
| Richard Bryan Riggsbee | CFO | 51,502 |
| Amy M. Rocklin | Former Chief Legal Officer | 82,182 |
| David H. Naemura | Former CFO | 93,936 |
| Douglas Edward Jones | Former COO | 104,362 |
| John Edward Adent | Former CEO | 371,608 |
| James C. Borel | Director | 96,347 |
| Jeffrey D. Capello | Director | 32,502 |
| Ronald D. Green | Director | 18,654 |
| Aashima Gupta | Director | 27,790 |
| Avi Pelossof | Director | 19,386 |
| William T. Boehm | Director | 47,913 |
| James P. Tobin | Director | 43,347 |
| Catherine E. Woteki | Director | 19,117 |
| Rafael A. Rodriguez | Director | 20,821 |
| Thierry Bernard | Director | 19,769 |
| Andrea F. Wainer | Director | 19,769 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Adent | $3.14M | $841.55K | $2.66M | $19 | $96 |
| FY2026 Nassif | $8.69M | $14.01M | $2.66M | $19 | $96 |
| FY2025 | $6.82M | -$457.68K | $2.24M | $13 | $79 |
| FY2025 Adent | $6.82M | -$457.68K | $2.24M | $13 | $79 |
| FY2025 Nassif | $0 | $0 | $2.24M | $13 | $79 |
| FY2024 | $7.22M | $4.50M | $2.99M | $29 | $84 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of May 31, 2026, we employed 2,636 people worldwide, with 1,346 located in North America and 1,290 international.”
Corporate history
Events identified from SEC filings